The treatment of EBV-negative and EBV-positive BL cells with inhibitors of histone deacetylase (HDAC) and DNA methyltransferase (DNMT), trichostatin A (TSA), and 5′-azacytidine (AZA), respectively, suggested that Bim-encoding mRNA level may be regulated via EBV-driven epigenetic modifications of the host cell chromatin. The gene discussed is BCL2L11; the disease is Burkitt lymphoma.